Written and maintained by CASRAI Editorial Board
Last updated
This page describes products and general use; it is not medical advice.
In short: a neuromodulation device delivers electrical, magnetic or pharmacological input to neural tissue, peripheral or central, to change nerve activity for a therapeutic purpose. This reference is for clinic staff, device buyers and students who need to tell the main device types apart and understand how the FDA regulates them.
What a neuromodulation device is
A neuromodulation device acts on neural tissue, either peripherally or centrally, to alter nerve activity for therapeutic purposes. The acting input may be electromagnetic or pharmacological (Source 1). Most of the devices discussed below are implanted stimulators, but external systems such as the transcranial magnetic stimulation (TMS) system and transcutaneous electrical nerve stimulation (TENS) are regulated in the same part of the Code of Federal Regulations.
Who uses it: implanted systems are used by clinical teams treating conditions such as Parkinson’s disease, epilepsy, chronic pain and overactive bladder (Source 1).
How implanted neuromodulation systems are built
The implanted systems in the FDA review share a common layout: one or more leads carrying electrode contacts, connected to an implanted pulse generator. The arrangement differs by type (Source 1):
- Deep brain stimulation (DBS): one or two leads, each with four or more contacts, connected to a pulse generator usually placed in the chest wall.
- Responsive neurostimulation (RNS): two leads with four contacts each; the generator is implanted in the skull.
- Vagus nerve stimulation (VNS): one lead with two contacts wrapped on the left vagus nerve in the neck; the generator sits in the chest.
Types of neuromodulation device and first FDA approval
The table lists implanted device types with the year of first FDA approval and the indications recorded in a peer-reviewed review of FDA approvals. Indications change over time, so treat the table as history, not current labelling.
| Type | First FDA approval | Indications recorded at first approval |
|---|---|---|
| Spinal cord stimulation (SCS) | 1984 | Chronic pain |
| Peripheral nerve stimulation (PNS) | 1989 | Chronic pain |
| Deep brain stimulation (DBS) | 1997 | Parkinson’s disease, essential tremor, dystonia, obsessive-compulsive disorder, epilepsy |
| Vagus nerve stimulation (VNS) | 1997 | Epilepsy, depression |
| Sacral neuromodulation | 1997 | Overactive bladder, urge incontinence, chronic fecal incontinence, non-obstructive urinary retention |
| Responsive neurostimulation (RNS) | 2013 | Epilepsy |
| Implantable tibial nerve stimulator | 2022 | Overactive bladder |
Source: Table 1 of the PMC review (Source 1). The review’s scope excludes noninvasive TMS and intrathecal pumps.
How neuromodulation devices are regulated by the FDA
The FDA sorts devices into risk classes. The review states that Class III, the highest-risk class, includes most neuromodulation devices. Class III devices generally need premarket approval (PMA), which usually requires at least one pivotal trial. A humanitarian device exemption (HDE) is the alternative pathway for rare conditions; DBS for primary dystonia was approved under an HDE in 2002 for patients aged 7 and older. The review also notes that these devices are primarily approved for adults (Source 1). See the CASRAI entry on the humanitarian use device and the guide to Class II medical devices for the neighbouring pathways.
Classification is by device type, not by the word “neuromodulation”
The classification regulations sit in 21 CFR Part 882, Subpart F (Source 2). The class differs by device type, so a stimulator for one purpose can sit in a different class from a similar-looking one for another:
| Device type (21 CFR section) | Class |
|---|---|
| Implanted cerebellar stimulator (882.5820) | III |
| Implanted phrenic nerve stimulator (882.5830) | III |
| Implanted intracerebral/subcortical stimulator for pain relief (882.5840) | III |
| Implanted spinal cord stimulator for bladder evacuation (882.5850) | III |
| Implanted neuromuscular stimulator (882.5860) | III |
| Implanted peripheral nerve stimulator for pain relief (882.5870) | II |
| Implanted spinal cord stimulator for pain relief (882.5880) | II |
| Transcranial magnetic stimulation system (882.5802) | II |
| Transcutaneous electrical nerve stimulator for pain relief (882.5890) | II |
| External vagal nerve stimulator for headache (882.5892) | II |
| Cranial electrotherapy stimulator (882.5800) | II for insomnia or anxiety; III for depression |
Source: eCFR, 21 CFR Part 882 Subpart F (Source 2). A spinal cord stimulator for pain relief is Class II by regulation even though the review says most neuromodulation devices are Class III; both statements hold because the review speaks generally and the regulation speaks per device type. A device’s specific clearance or approval is found in the FDA’s databases, not inferred from its type.
Related CASRAI device guides
- TMS coil: external magnetic stimulation hardware and its FDA status.
- TENS pads: electrode construction and FDA class for transcutaneous stimulation.
- Bone stimulators: electrical stimulation devices for bone healing.
- Medical device clinical trials: how device evidence is generated.
Common mistakes
- Assuming every neuromodulation device is Class III. The review says “most”; Part 882 lists several types as Class II (Source 2).
- Treating first-approval indications as current labelling. The table records what was approved first; check the FDA database for the current indications of a specific model.
- Assuming adult approval covers children. The review notes the devices are primarily approved for adults (Source 1).
- Treating external and implanted devices as one product class. TMS and TENS are external and regulated under their own sections; implanted systems have leads and an implanted generator.
Frequently asked questions
What is a neuromodulation device?
A device that acts on neural tissue, peripherally or centrally, to alter nerve activity for therapeutic purposes, using electromagnetic or pharmacological means (Source 1).
What are the main types?
Implanted types include spinal cord, peripheral nerve, deep brain, vagus nerve, sacral and responsive neurostimulation, plus an implantable tibial nerve stimulator; external examples include TMS and TENS (Sources 1 and 2).
Are neuromodulation devices Class III?
Most are, according to the review, but classification is by device type under 21 CFR Part 882 Subpart F, and several types are Class II (Sources 1 and 2).
What is an HDE?
A humanitarian device exemption is an alternative to PMA; DBS for primary dystonia was approved this way in 2002 (Source 1).
Sources
- Bridging the Gap in FDA Approval for Pediatric Neuromodulation Devices, PubMed Central PMC11853837, pmc.ncbi.nlm.nih.gov/articles/PMC11853837 (read 2026-11-08).
- Electronic Code of Federal Regulations, 21 CFR Part 882 Subpart F, Neurological Therapeutic Devices, ecfr.gov (read 2026-11-08).
